cobas c 311
Total Payments
$5.9M
Transactions
156
Doctors
0
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $154,588 | 8 | 0 |
| 2023 | $1.5M | 39 | 0 |
| 2022 | $1.2M | 16 | 0 |
| 2021 | $3.0M | 93 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.9M | 156 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CSF AD Markers in Health and Disease | Roche Diagnostics Corporation | $716,322 | 0 |
| RD005298 | Roche Diagnostics Operations, Inc. | $668,401 | 0 |
| CIMRD005298 | Roche Diagnostics Operations, Inc. | $505,679 | 0 |
| CIMRD005838 | Roche Diagnostics Operations, Inc. | $488,390 | 0 |
| RD002595: Pilot and Feasibility Heart Failure Prevention Study (2 of 3 Study) | Roche Diagnostics Corporation | $302,134 | 0 |
| CIMRD005847 | Roche Diagnostics Operations, Inc. | $251,416 | 0 |
| CIMRD005914 | Roche Diagnostics Operations, Inc. | $207,097 | 0 |
| Developmental Epidemiological Study of Children born through Reproductive Technology (DESCRT) | Roche Diagnostics Corporation | $184,364 | 0 |
| Longitudinal Early-onset AD Study (LEADS) | Roche Diagnostics Corporation | $129,489 | 0 |
| CIMRD005738 | Roche Diagnostics Operations, Inc. | $110,443 | 0 |
| RD003467 | Roche Diagnostics Operations, Inc. | $97,841 | 0 |
| CIMRD005615 | Roche Diagnostics Operations, Inc. | $96,552 | 0 |
| The IMpact of the Roche Elecsys sFlt-1/PlGF ratio on clinical decision making in suspected PreEclampsia (TIME PE) | Roche Diagnostics Corporation | $85,088 | 0 |
| RD004773 | Roche Diagnostics Operations, Inc. | $75,861 | 0 |
| CIMRD002685 | Roche Diagnostics Operations, Inc. | $72,348 | 0 |
| CIMRD005639 | Roche Diagnostics Operations, Inc. | $71,194 | 0 |
| CIMRD003369 | Roche Diagnostics Operations, Inc. | $70,535 | 0 |
| RD007183 STRONG-DM: Evaluation of a pragmatic NT-ProBNP-based heart failure screening strategy among patients with type 2 diabetes: STRONG-DM Study | Roche Diagnostics Corporation | $66,400 | 0 |
| CIMRD004773 | Roche Diagnostics Operations, Inc. | $65,006 | 0 |
| RD003708 | Roche Diagnostics Corporation | $49,162 | 0 |
Top Doctors Receiving Payments for cobas c 311
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Sacramento, CA | $5.9M | 156 |
Ad
Manufacturing Companies
Product Information
- Type Device
- Total Payments $5.9M
- Total Doctors 0
- Transactions 156
About cobas c 311
cobas c 311 is a device associated with $5.9M in payments to 0 healthcare providers, recorded across 156 transactions in the CMS Open Payments database. The primary manufacturer is Roche Diagnostics Corporation.
Payment data is available from 2021 to 2024. In 2024, $154,588 was paid across 8 transactions to 0 doctors.
The most common payment nature for cobas c 311 is "Unspecified" ($5.9M, 100.0% of total).
cobas c 311 is associated with 20 research studies, including "CSF AD Markers in Health and Disease" ($716,322).